Seaport Therapeutics
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
We do not have this company's yearly figures yet, so its profit, growth, price and debt cannot be judged here.
Money in, money out
What Seaport Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2024 to $0 in 2025, with -$74.9 million of profit last year.
Seaport Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Seaport Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.8× · Expensive | ||
 Regeneron Pharmaceuticals | 21.8× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.3× · Fair price |
AI analysis
An AI analyst reads Seaport Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2024 | 2025 |
|---|---|---|
| 0 | 0 | |
| – | – | |
| -52 | -87 | |
| -52 | -86 | |
| -47 | -75 | |
| -1.21 | – | |
| – | – | |
| – | – | |
| – | – |
Balance sheet
| In millions of USD | 2024 | 2025 |
|---|---|---|
| Total assets | 316 | 249 |
| Cash | 309 | 46 |
| Total debt | 5 | 5 |
| Total liabilities | 341 | 342 |
| -25 | -93 | |
| 39 | – | |
| – | – | |
| 188.7% | 80.9% |
Cash flow
| In millions of USD | 2024 | 2025 |
|---|---|---|
| -30 | -78 | |
| 0 | 0 | |
| -30 | -78 | |
| Dividends paid | – | – |
| – | – | |
| 15 | 7 |
Valuation
- –
- –
- –
- –
- –
- –
- –
- –
- –
- –
Profitability
- –
- –
- –
- –
- –
- –
- –
- –
- –
- –
Growth
- –
- –
- –
- –
- –
Financial health
- –
- –
- –
- –
- –
- –
- –
News
Nvidia ticks up even as Seaport reiterates Sell rating and says competition is 'mounting'Seeking Alpha · Oct 23, 2026Seaport starts bullish on Marvell, Semtech, and On SemiSeeking Alpha · Sep 23, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
Not enough data
Questions about Seaport Therapeutics
Is Seaport Therapeutics a good stock to buy?
We do not have this company's yearly figures yet, so its profit, growth, price and debt cannot be judged here. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Seaport Therapeutics AI analysis
What does Seaport Therapeutics do?
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. It is in Biotechnology.
Does Seaport Therapeutics pay a dividend?
No. Seaport Therapeutics does not pay a dividend at the moment.
Is Seaport Therapeutics stock halal?
Yes. Seaport Therapeutics passes our halal screen: its business is permitted and its debt is 0.5% of its market value, under the 30% limit. How we check
Who are Seaport Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Seaport Therapeutics's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.